Compare DexCom, Inc. (DXCM) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs GoPro Inc — how do they compare? DexCom, Inc. trades at $77.98 (market cap $28.06B), while GoPro Inc trades at $0.67 (market cap $122.03M). The key difference: DexCom, Inc. is far larger — about 229.9× GoPro Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | GPRO | |
|---|---|---|
Market Cap | $28.06B | $122.03M |
Sector | Health | Technology |
52-Week High | $89.53 | $2.88 |
52-Week Low | $54.84 | $0.64 |
Enterprise Value | $27.03B | $169.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
GoPro (GPRO) trades at $0.6732, down 3.53% on the day, reflecting persistent financial stress with a net income margin of -20.7% and negative cash flow. The company is undergoing a strategic review for potential sale or merger, announced May 11, 2026, after receiving inbound interest. Technical indicators are bearish, with moving averages signaling continued downward pressure, while recent product launches like the MISSION 1 series aim to revive growth amid declining revenues.
The outlook hinges on the strategic review outcome; a successful sale could provide shareholder value, but ongoing losses and high burn rate pose significant risks. Investors face binary event-driven speculation, with analyst consensus mixed and substantial downside if restructuring fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
